公开(公告)号：MX9503979A

公开(公告)日：1997-01-31

申请号：MX9503979

申请日：1995-01-23

Applicant: BAXTER INT

Inventor： MARTIS LEO ,  BURKE RON ,  SHOCKLEY TY ,  HENDERSON LEE W ,  FALLER BERNADETTE

IPC: A61K31/715 ,  A61K33/14 ,  A61M1/14 ,  A61M1/28 ,  A61M01/28

Abstract: Se describe una solucion de diálisis peritoneal que comprende como agentes osmoticos, de aproximadamente 2.0 a aproximadamente 6.0% (p/v) de maltodextrinas y de aproximadamente 0.25 a aproximadamente 2.0% (p/v) de aminoácidos. La solucion de diálisis peritoneal también incluirá otros tales como sodio, cloruro, lactato, bicarbonato, calcio y magnesio.

公开(公告)号：AU2655195A

公开(公告)日：1996-01-25

申请号：AU2655195

申请日：1995-05-25

Applicant: BAXTER INT

Inventor： MARTIS LEO ,  HENDERSON LEE W

IPC: A61K9/08 ,  A61K31/19 ,  A61K31/194 ,  A61K31/70 ,  A61K31/7004 ,  A61K33/00 ,  A61K33/10 ,  A61K33/14 ,  A61M1/28 ,  A61P7/08 ,  A61P13/12 ,  A61M1/16

Abstract: A peritoneal dialysis solution that is biochemically balanced to correct metabolic acidosis associated with chronic renal failure in a more physiological manner. The peritoneal dialysis solution has a physiological pH, e.g. pH of 70 to 74 and contains bicarbonate at a concentration that is found in normal blood. Additionally, the solution contains carbon dioxide at a partial pressure that is similar to partial pressure of carbon dioxide found in normal blood. The peritoneal dialysis solution also contains a weak acid with a pKa of less than 5.0.

公开(公告)号：CA2129991A1

公开(公告)日：1994-07-07

申请号：CA2129991

申请日：1993-12-10

Applicant: BAXTER INT

Inventor： MARTIS LEO ,  BURKE RON ,  FAICT DIRK

IPC: A61K9/08 ,  A61K31/70 ,  A61K33/00 ,  A61K38/00 ,  A61K38/01 ,  A61K38/02 ,  A61K47/26 ,  A61K47/42 ,  A61M1/14 ,  A61M1/28 ,  A61P7/08

Abstract: 2129991 9414468 PCTABS00032 The present invention provides an improved dialysis solution. The improved dialysis solution provides for the use of specific polypeptides as an osmotic agent with an additional osmotic agent such as dextrose. To this end, the present invention provides, in an embodiment, a peritoneal dialysis solution comprising as osmotic agents approximately 0.25 to about 4.0 % (w/v) polypeptides and approximately 0.5 % to about 4.0 % (w/v) dextrose. The polypeptides have well defined characteristics.